<DOC>
	<DOC>NCT00299845</DOC>
	<brief_summary>Proton pump inhibitors are administered to children as off-label use in Japan. The purpose of this study is to evaluate the effects of CYP2C19 genotypes on pharmacokinetic /pharmacodynamic profiles of PPI in children. The results will provide the beneficial information for the individualized medicine of PPI in children.</brief_summary>
	<brief_title>Randomized Trial for Pharmacogenomics-based Proton Pump Inhibitor Therapy in Children</brief_title>
	<detailed_description />
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<mesh_term>Lansoprazole</mesh_term>
	<mesh_term>Dexlansoprazole</mesh_term>
	<mesh_term>Proton Pump Inhibitors</mesh_term>
	<criteria>Patients with gastroesophageal reflux The patient's parent or guardian gives written informed consent including pharmacogenomic analysis The patient is willing and able to give assent to participate. Serious hepatic disease, pulmonary disease, renal disease and blood disorder Inadequate clinical conditions</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>September 2006</verification_date>
	<keyword>gastroesophageal reflux</keyword>
	<keyword>children</keyword>
	<keyword>lansoprazole</keyword>
	<keyword>cytochrome P450 2C19 (CYP2C19)</keyword>
	<keyword>pharmacogenomics</keyword>
	<keyword>genetic polymorphisms</keyword>
	<keyword>individualized medicine</keyword>
	<keyword>pharmacokinetics/dynamics</keyword>
</DOC>